S&P 500 index data: S&P 500 Copyright ©
All data supplied by Morningstar Real-Time Data. U.S. intraday real-time exchange quotes are sourced from BATS when available. End-of-day quotes for Nasdaq, NYSE, and Amex securities will appear 15 minutes after close. Graph times are Eastern Standard. © Copyright Morningstar, Inc .
|Start Premium Trial||Register For Free|
|P||F||Fund Financial Data (13,000+ funds)|
|P||F||Stock Financial Data (7,000+ stocks)|
|P||F||Stock and Fund Screeners (basic)|
|P||F||Investing Articles and Market Commentary|
|P||F||Articles Archive (>30 days)|
|P||F||Discuss (dozens of stock, fund, bond, and general bulletin boards)|
|P||F||Portfolio Manager (basic)|
|P||F||Morningstar Investment Classroom|
|P||F||Access Your Portfolio Anytime, Anywhere via Your Mobile Device|
|P||Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)|
|P||Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)|
|P||Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)|
|P||Portfolio Monitor (monthly and on-demand personalized portfolio statements)|
|P||Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters|
|P||Discounts on Morningstar newsletters, books, seminars, and more|
Join Morningstar today. It's Free.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.
|Verastem Acquires Rights to Cancer Stem Cell Inhibitor VS-4718 (2014/2/25)|
|Verastem Issued U.S. Patent Covering VS-4718 Composition of Matter ()|
|Verastem Reports Year-End 2013 Financial Results (2014/3/6)|
|Nature Immunology Paper Highlights Potential Role of FAK Inhibition in Hematological Malignancies (2014/2/10)|
|Verastem Reports Third Quarter 2013 Financial and Corporate Results (2013/11/12)|
|Cancer Research Publication Highlights Importance of Merlin Loss and Cancer Stem Cells in Mesothelioma (2014/2/24)|
|Verastem Reports Second Quarter 2013 Financial and Corporate Results (2013/8/13)|
|Verastem Initiates COMMAND: A Registration-Directed Trial of Defactinib in Patients with Mesothelioma (2013/9/10)|
|Verastem to Present at Upcoming Scientific and Investor Conferences ()|
|Verastem Initiates Phase 2 Trial of Defactinib in Lung Cancer (2013/9/26)|
Click above to view more mutual fund data and stats for 4718 - Waseda Academy Co Ltd.